Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings
Genprex (NASDAQ: GNPX) announced the publication of their research collaborators' abstract in Cancer Research's online Proceedings supplement. The abstract, which will be presented at the 2025 AACR Annual Meeting, showcases positive preclinical data for Reqorsa® Gene Therapy in treating KRASG12C mutant non-small cell lung cancer (NSCLC).
The research demonstrates that TUSC2 gene therapy (REQORSA) effectively overcomes sotorasib acquired resistance in KRASG12C mutant NSCLC mouse xenografts. Key findings show that TUSC2 transfection reduced colony formation in resistant cell lines, increased apoptosis, and decreased organoid viability. The treatment showed significant antitumor efficacy, particularly when combined with sotorasib in resistant tumors.
Genprex (NASDAQ: GNPX) ha annunciato la pubblicazione dell'abstract dei loro collaboratori di ricerca nel supplemento online degli Atti di Cancer Research. L'abstract, che verrà presentato al 2025 AACR Annual Meeting, evidenzia dati preclinici positivi per la terapia genica Reqorsa® nel trattamento del carcinoma polmonare non a piccole cellule (NSCLC) con mutazione KRASG12C.
La ricerca dimostra che la terapia genica TUSC2 (REQORSA) supera efficacemente la resistenza acquisita a sotorasib nei xenotrapianti murini di NSCLC con mutazione KRASG12C. I risultati principali mostrano che la trasfezione di TUSC2 ha ridotto la formazione di colonie nelle linee cellulari resistenti, aumentato l'apoptosi e diminuito la vitalità degli organoidi. Il trattamento ha evidenziato un'efficacia antitumorale significativa, soprattutto se combinato con sotorasib nei tumori resistenti.
Genprex (NASDAQ: GNPX) anunció la publicación del resumen de sus colaboradores de investigación en el suplemento en línea de los Proceedings de Cancer Research. El resumen, que será presentado en la Reunión Anual AACR 2025, muestra datos preclínicos positivos para la terapia génica Reqorsa® en el tratamiento del cáncer de pulmón no microcítico (NSCLC) con mutación KRASG12C.
La investigación demuestra que la terapia génica TUSC2 (REQORSA) supera eficazmente la resistencia adquirida a sotorasib en xenoinjertos de ratón con NSCLC mutante KRASG12C. Los hallazgos clave indican que la transfección con TUSC2 redujo la formación de colonias en líneas celulares resistentes, aumentó la apoptosis y disminuyó la viabilidad de los organoides. El tratamiento mostró una eficacia antitumoral significativa, especialmente cuando se combinó con sotorasib en tumores resistentes.
Genprex (NASDAQ: GNPX)는 연구 협력자들의 초록이 Cancer Research 온라인 프로시딩 보조판에 게재되었음을 발표했습니다. 이 초록은 2025 AACR 연례회의에서 발표될 예정이며, KRASG12C 돌연변이 비소세포폐암(NSCLC) 치료를 위한 Reqorsa® 유전자 치료의 긍정적인 전임상 데이터를 보여줍니다.
연구 결과에 따르면 TUSC2 유전자 치료(REQORSA)는 KRASG12C 돌연변이 NSCLC 마우스 이종이식 모델에서 소토라십(sotorasib)에 대한 획득 저항성을 효과적으로 극복합니다. 주요 발견은 TUSC2 형질도입이 저항성 세포주에서 집락 형성을 감소시키고, 세포자멸사를 증가시키며, 오가노이드 생존율을 낮춘다는 점입니다. 이 치료법은 특히 저항성 종양에서 소토라십과 병용 시 뛰어난 항종양 효과를 보였습니다.
Genprex (NASDAQ : GNPX) a annoncé la publication du résumé de ses collaborateurs de recherche dans le supplément en ligne des Proceedings de Cancer Research. Ce résumé, qui sera présenté lors du Congrès annuel AACR 2025, met en avant des données précliniques positives concernant la thérapie génique Reqorsa® pour le traitement du cancer du poumon non à petites cellules (NSCLC) muté KRASG12C.
La recherche démontre que la thérapie génique TUSC2 (REQORSA) surmonte efficacement la résistance acquise au sotorasib dans des xénogreffes murines de NSCLC muté KRASG12C. Les résultats clés montrent que la transfection de TUSC2 réduit la formation de colonies dans les lignées cellulaires résistantes, augmente l'apoptose et diminue la viabilité des organoïdes. Le traitement a montré une efficacité antitumorale significative, notamment lorsqu'il est combiné au sotorasib dans les tumeurs résistantes.
Genprex (NASDAQ: GNPX) gab die Veröffentlichung des Abstracts ihrer Forschungspartner im Online-Supplement der Cancer Research Proceedings bekannt. Das Abstract, das auf dem 2025 AACR Annual Meeting vorgestellt wird, zeigt positive präklinische Daten zur Reqorsa® Gen-Therapie bei der Behandlung von KRASG12C-mutiertem nicht-kleinzelligem Lungenkrebs (NSCLC).
Die Forschung zeigt, dass die TUSC2-Gen-Therapie (REQORSA) die erworbene Resistenz gegen Sotorasib bei KRASG12C-mutierten NSCLC-Maus-Xenotransplantaten wirksam überwindet. Wichtige Ergebnisse zeigen, dass die TUSC2-Transfektion die Koloniebildung in resistenten Zelllinien reduzierte, die Apoptose erhöhte und die Organoid-Vitalität verringerte. Die Behandlung zeigte eine signifikante antitumorale Wirksamkeit, insbesondere in Kombination mit Sotorasib bei resistenten Tumoren.
- Positive preclinical efficacy data showing Reqorsa's effectiveness against resistant lung cancer
- Successful demonstration of synergistic antitumor effects when combining Reqorsa with sotorasib
- Recognition from major scientific journal (Cancer Research) and AACR conference
- Still in preclinical stage, requiring further clinical trials before potential commercialization
- Results to mouse xenografts and laboratory studies, pending human trial validation
Insights
REQORSA showing promising ability to overcome KRAS inhibitor resistance in lung cancer through multiple tumor-suppressing mechanisms in preclinical studies.
The publication in Cancer Research and upcoming AACR presentation represent meaningful scientific validation for Genprex's REQORSA gene therapy approach. The preclinical data demonstrates multi-mechanistic effectiveness against KRASG12C mutant NSCLC that has developed resistance to sotorasib (Lumakras). This addresses a critical clinical challenge - while KRAS inhibitors initially work, patients inevitably develop resistance.
What's particularly impressive is REQORSA's demonstrated activity through several complementary mechanisms:
- Reducing colony formation in resistant cell lines
- Significantly increasing apoptosis (programmed cell death) in resistant cells
- Decreasing viability in patient-derived xenograft organoids
- Controlling tumor growth in resistant models
The TUSC2 tumor suppressor gene delivered by REQORSA functions through multiple pathways - inhibiting MAPK and mTOR signaling, arresting cancer cell growth, inducing cell death, and activating immune responses. This multi-pronged approach may explain its effectiveness against resistance mechanisms.
Most notably, the research showed synergistic antitumor effects when combining REQORSA with sotorasib in resistant tumors. This suggests potential for combination therapy strategies that could extend the clinical benefit of existing KRAS inhibitors. While these findings remain preclinical and require validation in human studies, they represent a promising approach to addressing one of the most challenging aspects of targeted cancer therapy.
Publication of positive preclinical data provides scientific validation for Genprex's lead drug candidate addressing critical resistance mechanisms in lung cancer.
This abstract publication provides important scientific validation for Genprex's REQORSA gene therapy program. Selection for both publication in Cancer Research and presentation at the prestigious AACR Annual Meeting elevates the visibility of this small-cap biotech's research among cancer specialists and industry stakeholders.
The data addresses a significant unmet need in oncology - acquired resistance to KRAS inhibitors. KRAS mutations were long considered "undruggable" until Lumakras (sotorasib) became the first FDA-approved KRAS inhibitor, but resistance inevitably develops. REQORSA demonstrates potential to overcome this resistance through a novel approach: delivering the tumor suppressor gene TUSC2.
Two aspects of the data stand out from a development perspective:
- REQORSA showed efficacy as monotherapy in resistant models
- REQORSA demonstrated synergistic effects when combined with sotorasib
This provides multiple potential development pathways - either as a standalone treatment after resistance develops or in combination to prevent/delay resistance emergence.
The robust nature of the preclinical evidence - showing efficacy across multiple model systems (cell lines, xenografts, patient-derived models) and through multiple mechanisms - strengthens the scientific foundation for further development.
For a company with
Research Journal Features Genprex Collaborators' Abstract Detailing Positive Preclinical Data on the Use of
Reqorsa® Gene Therapy for the Treatment of Lung Cancer
Genprex collaborators will present the published abstract in a poster presentation at the 2025 AACR Annual Meeting being held April 25-30, 2025 in
"We are pleased to have our collaborators' abstract selected for both publication and presentation before the world's top cancer researchers, investigators and healthcare professionals," said Ryan Confer, President and Chief Executive Officer at Genprex. "This publication highlights research-driven advances against cancer, and we are gratified to be featured among those advances. We look forward to this week's presentation of positive preclinical data on our lead drug candidate, REQORSA, as a potential therapeutic treatment for Ras inhibitor resistant lung cancer."
The featured Genprex-supported poster to be presented at AACR 2025:
Title: Overcoming sotorasib acquired resistance in KRASG12C mutant NSCLC by TUSC2 gene therapy
Session Category: Experimental and Molecular Therapeutics
Session Title: Drug Resistance in Molecular Targeted Therapies 3
Session Date and Time: Tuesday, April 29 from 2-5 p.m. CT
Location: Poster Section 17
Poster Board Number: 12
Abstract Presentation Number: 5517
The featured Genprex-supported abstract to be presented at AACR 2025:
Acquired resistance (AR) to Lumakras® (sotorasib), the first FDA-approved KRASi, poses a significant challenge in the treatment of KRASG12C mutant NSCLC. Despite initial responses, patients invariably develop resistance, necessitating alternative therapeutic strategies. The mechanisms underlying AR include the emergence of additional mutations in the KRAS gene, reactivation of the KRAS pathway, or activation of alternative signaling pathways. TUSC2, a potent tumor suppressor gene with immunogenic properties, exhibits multifunctional activity by inhibiting downstream signaling pathways, including MAPK and mTOR; arresting the growth and proliferation of cancer cells; inducing tumor cell death; and activating innate and adaptive immune responses. In this study, researchers demonstrated that TUSC2 gene therapy (REQORSA) effectively overcomes sotorasib AR in KRASG12C mutant NSCLC mouse xenografts.
The data indicate that TUSC2 transfection significantly reduced colony formation in two AR cell lines. Transfection of TUSC2 also markedly increased apoptosis in AR cells. Re-expression of TUSC2 into AR PDXOs significantly decreased the viability of organoids compared with the empty vector. The H23AR tumors exhibited significantly lower sensitivity to sotorasib than their parental counterparts. However, treatment with REQORSA was highly effective in controlling tumor growth compared to treatment with sotorasib alone or the control groups. REQORSA alone also exhibited a strong antitumor effect on TC314AR PDXs. Sotorasib alone showed no significant antitumor activity in these models. However, a synergistic antitumor effect was observed when TC314AR PDX tumors were treated with the combination of REQORSA and sotorasib.
In conclusion, researchers demonstrated that REQORSA, alone or in combination with sotorasib, induced apoptosis, inhibited colony formation, and showed significant antitumor efficacy in KRASG12C mutant sotorasib-acquired resistant xenograft and PDX tumors.
About Reqorsa® Gene Therapy
REQORSA (quaratusugene ozeplasmid) consists of a plasmid containing the TUSC2 gene encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company's Oncoprex® Delivery System), which has a positive charge. REQORSA is injected intravenously and specifically targets cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue. Laboratory studies conducted at MD Anderson show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2024.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: REQORSA's potential as a therapeutic treatment for Ras inhibitor resistant lung cancer; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals, the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; the effects of any strategic research and development prioritization initiatives, and any other strategic alternatives or other efforts that Genprex takes or may take in the future that are aimed at optimizing and re-focusing Genprex's diabetes, oncology and/or other clinical development programs including prioritization of resources, and the extent to which Genprex is able to implement such efforts and initiatives successfully to achieve the desired and intended results thereof; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-announces-research-collaborators-abstract-published-in-cancer-research-supplement-proceedings-302432197.html
SOURCE Genprex, Inc.
FAQ
What are the key findings of Genprex's (GNPX) Reqorsa therapy in treating resistant lung cancer?
How does Genprex's (GNPX) TUSC2 gene therapy work against NSCLC?
When will Genprex (GNPX) present their Reqorsa research at AACR 2025?
What is the significance of Genprex's (GNPX) abstract publication in Cancer Research?
